In the latest edition of AMA Update, a panel of experts gathered to shed light on the pressing topic of long COVID and its implications for physicians, residents, medical students, and patients. The virtual discussion featured renowned immunobiologist, Akiko Iwasaki, PhD, Sterling Professor of Immunobiology at Yale University, as the guest speaker. The session was hosted by Todd Unger, AMA Chief Experience Officer.

Long COVID, also known as post-acute sequelae of SARS-CoV-2 infection (PASC), has emerged as a significant concern among individuals recovering from COVID-19. Dr. Iwasaki delved into the intricate details of this condition, addressing the causes, potential dangers, and risk factors associated with long COVID.

Regarding the causes of long COVID, Dr. Iwasaki highlighted the persistent activation of the immune system as a key factor. She pointed out that even after the acute phase of the viral infection subsides, some patients experience a prolonged immune response, leading to the chronic symptoms associated with long COVID.

Addressing concerns about the potential dangers of long COVID, Dr. Iwasaki acknowledged that while most individuals recover completely within weeks or months, some may experience persistent symptoms that impact their daily lives. These symptoms can range from fatigue, brain fog, and respiratory issues to organ damage. As such, it is crucial to understand the long-term effects of the virus and develop strategies to manage and treat these cases effectively.

Dr. Iwasaki shared insights into the demographics most likely to develop long COVID. Although older adults and individuals with pre-existing health conditions are generally more susceptible, she emphasized that long COVID can affect people of all ages and health statuses. The variability in symptoms and duration make it vital for healthcare professionals to be aware of the potential risks and provide appropriate support for their patients.

During the discussion, the panel also touched upon pediatric long COVID, a concerning issue for parents and medical practitioners alike. While research on this topic is still evolving, early findings suggest that children can experience long-term symptoms following a COVID-19 infection. The prevalence and characteristics of pediatric long COVID are being actively investigated to better understand its impact and develop targeted treatment approaches.

As the session concluded, Dr. Iwasaki highlighted the need for further research to fully comprehend the mechanisms underlying long COVID. She stressed the importance of collaboration between scientists, healthcare professionals, and public health officials to improve diagnosis, treatment, and support for individuals grappling with this condition.

The AMA Update provided a comprehensive overview of the latest research findings and discussions surrounding long COVID. By bringing together esteemed experts like Dr. Iwasaki, the event aimed to equip healthcare professionals with knowledge and empower them to address the challenges presented by this long-term consequence of COVID-19.